Table 2. Treatment elements for... | American Society of Hematology

Table 2.

Treatment elements for high-risk ALL patients in the GMALL studies 04/89 and 05/93

Therapy	Dose	Route	Days
Induction
Phase I
Prednisolone	3 × 20 mg/m²	PO	1-28
Vincristine	2 mg	IV	1, 8, 15, 22
Daunorubicin	45 mg/m²	IV	1, 8, 15, 22
L-asparaginase	5000 E/m²	IV	15-28
Methotrexate	15 mg	IT	1
Phase II
04/89 and 05/93 low-risk patients and high-risk patients older than 50 y
Cyclophosphamide	650 mg/m²^*	IV	29, 43, 57
Cytarabine	75 mg/m²	IV	31-34, 38-41, 45-48, 52-55
6-Mercaptopurine	60 mg/m²	PO	29-57
Methotrexate	15 mg	IT	31, 38, 45, 52
05/93 high-risk patients younger than 50 y (wk 6)
Cytarabine	3 g/m²	IV	1-4 (12 hourly)
Mitoxantrone	10 mg/m²	IV	3-5
Reinduction
Phase I
Prednisone	3 × 20 mg/m²	PO	1-28
Vincristine	2 mg	IV	1, 8, 15, 22
Doxorubicin	25 mg/m²	IV	1, 8, 15, 22
Methotrexate	15 mg	IT	1
Cytarabine	40 mg	IT	1
Dexamethasone	4 mg	IT	1
Phase II
Cyclophosphamide	650 mg/m²^*	IV	29
Cytarabine	75 mg/m²	IV	31-34, 38-41
Thioguanine	60 mg/m²	PO	29-42
Methotrexate	15 mg	IT	29
Cytarabine	40 mg	IT	29
Dexamethasone	4 mg	IT	29
Consolidation
HD cytarabine/mitoxantrone (wk 13 of 04/89; wk 33 of 05/93)
Cytarabine	1 g/m²	IV	1-4 (12 hourly)
Mitoxantrone	10 mg/m²	IV	2-5
HD methotrexate/L-asparaginase (wk 13, 15, 17 of 04/89, wk 13, 15, 39, 41 of 05/93)
Methotrexate	1500 mg/m²	IV	1
L-asparaginase	10 000 IU/m²	IV	2
6-Mercaptopurine (wk 13, 15 of 05/93)
6-Mercaptopurine	25 mg/m²	PO	1-5
Cyclophosphamide/Ara-C (wk 17, 45 of 05/93)
Cyclophosphamide	1000 mg/m²	IV	1
Cytarabine	500 mg/m²	IV	1 (24-h infusion)
Teniposide/cytarabine (wk 31, 35 of 04/89, wk 51 of 05/93)
Teniposide	60 mg/m²	IV	1-5
Cytarabine	75 mg/m²	IV	Day 1-5

Therapy	Dose	Route	Days
Induction
Phase I
Prednisolone	3 × 20 mg/m²	PO	1-28
Vincristine	2 mg	IV	1, 8, 15, 22
Daunorubicin	45 mg/m²	IV	1, 8, 15, 22
L-asparaginase	5000 E/m²	IV	15-28
Methotrexate	15 mg	IT	1
Phase II
04/89 and 05/93 low-risk patients and high-risk patients older than 50 y
Cyclophosphamide	650 mg/m²^*	IV	29, 43, 57
Cytarabine	75 mg/m²	IV	31-34, 38-41, 45-48, 52-55
6-Mercaptopurine	60 mg/m²	PO	29-57
Methotrexate	15 mg	IT	31, 38, 45, 52
05/93 high-risk patients younger than 50 y (wk 6)
Cytarabine	3 g/m²	IV	1-4 (12 hourly)
Mitoxantrone	10 mg/m²	IV	3-5
Reinduction
Phase I
Prednisone	3 × 20 mg/m²	PO	1-28
Vincristine	2 mg	IV	1, 8, 15, 22
Doxorubicin	25 mg/m²	IV	1, 8, 15, 22
Methotrexate	15 mg	IT	1
Cytarabine	40 mg	IT	1
Dexamethasone	4 mg	IT	1
Phase II
Cyclophosphamide	650 mg/m²^*	IV	29
Cytarabine	75 mg/m²	IV	31-34, 38-41
Thioguanine	60 mg/m²	PO	29-42
Methotrexate	15 mg	IT	29
Cytarabine	40 mg	IT	29
Dexamethasone	4 mg	IT	29
Consolidation
HD cytarabine/mitoxantrone (wk 13 of 04/89; wk 33 of 05/93)
Cytarabine	1 g/m²	IV	1-4 (12 hourly)
Mitoxantrone	10 mg/m²	IV	2-5
HD methotrexate/L-asparaginase (wk 13, 15, 17 of 04/89, wk 13, 15, 39, 41 of 05/93)
Methotrexate	1500 mg/m²	IV	1
L-asparaginase	10 000 IU/m²	IV	2
6-Mercaptopurine (wk 13, 15 of 05/93)
6-Mercaptopurine	25 mg/m²	PO	1-5
Cyclophosphamide/Ara-C (wk 17, 45 of 05/93)
Cyclophosphamide	1000 mg/m²	IV	1
Cytarabine	500 mg/m²	IV	1 (24-h infusion)
Teniposide/cytarabine (wk 31, 35 of 04/89, wk 51 of 05/93)
Teniposide	60 mg/m²	IV	1-5
Cytarabine	75 mg/m²	IV	Day 1-5

1000 mg/m² in 05/93.